Home » Business News » 2012 » April » April 6, 2012

Novo Nordisk A/S : Victoza(R) label in the US updated to include data showing superior efficacy when compared to Januvia(R)

April 6, 2012 - Bagsvaerd, Denmark

Novo Nordisk today announced that the USFood and Drug Administration (FDA) hasapproved to update the product label for Victoza® (liraglutide [rDNA]injection) to include data showing superior blood sugar control and weightreduction when compared to Januvia® (sitagliptin).

Company announcement 22 2012:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information:


Mike Rulis
Tel: (+45) 3079 3573
Email Contact


Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

In North America:
Ambre Morley
Tel: (+1) 609 216-5240
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


Comment on this story